Intermuscular extremity myxoid liposarcoma can be managed by marginal resection following neoadjuvant radiotherapy. Issue 2 (February 2023)
- Record Type:
- Journal Article
- Title:
- Intermuscular extremity myxoid liposarcoma can be managed by marginal resection following neoadjuvant radiotherapy. Issue 2 (February 2023)
- Main Title:
- Intermuscular extremity myxoid liposarcoma can be managed by marginal resection following neoadjuvant radiotherapy
- Authors:
- Perera, Jonathan R.
AlFaraidy, Meshal
Ibe, Izuchukwu
Aoude, Ahmed
Acem, Ibtissam
van de Sande, Michiel A.J.
Dessureault, Mireille
Turcotte, Robert E.
Mottard, Sophie
Basile, Georges
Isler, Marc
Saint-Yves, Hugo
Eastley, Nicholas
Stevenson, Jonathan
Houdek, Matthew T.
Chung, Peter W.M.
Griffin, Anthony M.
Ferguson, Peter
Wunder, Jay S.
Tsoi, Kim M. - Abstract:
- Abstract: Background: Compared with other soft tissue sarcomas, myxoid liposarcoma (MLS) occurs in younger patients, has a propensity for intermuscular locations and is highly radiosensitive. With pre-operative radiotherapy, intermuscular MLS demonstrates substantial volume reduction and can be easily separated from surrounding tissues during resection. However, it is unclear whether marginal excision of MLS is oncologically safe. This study aimed to assess the association between margins and survival in irradiated, intermuscular MLS. Methods: The study identified 198 patients from seven sarcoma centres with a first presentation of localized, extremity, intermuscular MLS that received pre-operative radiotherapy and was diagnosed between 1990 and 2017. Patient and treatment characteristics, radiological and histological responses to neoadjuvant treatment and clinical surveillance were recorded. Results: Margins were microscopically positive in 11% (n = 22), <1.0 mm in 15% (n = 29) and ≥1.0 mm in 72% (n = 143). There was no association between margin status and local recurrence-free, metastasis-free or overall survival. This finding held true even in patients at higher risk of worse overall survival based on multivariable analysis (% round cell≥5%, percentage ellipsoid tumour volume change ≤ -60.1%). Conclusion: Irradiated, extremity, intermuscular myxoid liposarcoma can safely undergo marginal resection without compromising oncologic control. Abstract : FollowingAbstract: Background: Compared with other soft tissue sarcomas, myxoid liposarcoma (MLS) occurs in younger patients, has a propensity for intermuscular locations and is highly radiosensitive. With pre-operative radiotherapy, intermuscular MLS demonstrates substantial volume reduction and can be easily separated from surrounding tissues during resection. However, it is unclear whether marginal excision of MLS is oncologically safe. This study aimed to assess the association between margins and survival in irradiated, intermuscular MLS. Methods: The study identified 198 patients from seven sarcoma centres with a first presentation of localized, extremity, intermuscular MLS that received pre-operative radiotherapy and was diagnosed between 1990 and 2017. Patient and treatment characteristics, radiological and histological responses to neoadjuvant treatment and clinical surveillance were recorded. Results: Margins were microscopically positive in 11% (n = 22), <1.0 mm in 15% (n = 29) and ≥1.0 mm in 72% (n = 143). There was no association between margin status and local recurrence-free, metastasis-free or overall survival. This finding held true even in patients at higher risk of worse overall survival based on multivariable analysis (% round cell≥5%, percentage ellipsoid tumour volume change ≤ -60.1%). Conclusion: Irradiated, extremity, intermuscular myxoid liposarcoma can safely undergo marginal resection without compromising oncologic control. Abstract : Following pre-operative radiotherapy, extremity intermuscular myxoid liposarcoma can be marginally resected without compromising local recurrence-free, metastasis-free or overall survival. … (more)
- Is Part Of:
- European journal of surgical oncology. Volume 49:Issue 2(2023)
- Journal:
- European journal of surgical oncology
- Issue:
- Volume 49:Issue 2(2023)
- Issue Display:
- Volume 49, Issue 2 (2023)
- Year:
- 2023
- Volume:
- 49
- Issue:
- 2
- Issue Sort Value:
- 2023-0049-0002-0000
- Page Start:
- 362
- Page End:
- 367
- Publication Date:
- 2023-02
- Subjects:
- Oncology -- Periodicals
Cancer -- Surgery -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- surgery -- Periodicals
Cancer -- Chirurgie -- Périodiques
Cancérologie -- Périodiques
Oncologie
Chirurgie (geneeskunde)
Electronic journals
Electronic journals -- Sciences
Electronic journals -- Medicine
Electronic journals
616.994059005 - Journal URLs:
- http://www.ejso.com/ ↗
http://www.sciencedirect.com/science/journal/07487983 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/07487983 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0720048X ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0748-7983;screen=info;ECOIP ↗
http://www.elsevier.com/journals ↗
http://www.harcourt-international.com/journals ↗
http://www.idealibrary.com/cgi-bin/links/toc/ejso ↗ - DOI:
- 10.1016/j.ejso.2022.09.008 ↗
- Languages:
- English
- ISSNs:
- 0748-7983
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.745500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 25947.xml